European Summit: The Role of Vaccines and Diagnostics in addressing AMR
QEII Conference Centre, London
8th-9th June 2017

Programme

0900
REGISTRATION AND REFRESHMENTS

1020
Welcome and opening remarks
1030
Keynote presentation: Antimicrobial Resistance – where to next?
Professor John Watson, Deputy Chief Medical Officer, Department of Health, London

Plenary session - How can vaccines and diagnostics to help win the battle against antimicrobial resistance?
1100
Update on the potential and actual role of vaccines in reducing antimicrobial resistance
Dr David McIntosh, Honorary Clinical Senior Lecturer, Imperial College, London
1125
Diagnostics
Dr Fiona Carragher, Deputy Chief Scientific Officer, NHS England, London
1150
Q&A

1200
REFRESHMENTS, NETWORKING AND POSTERS

Parallel sessions
Diagnostic solutions for antimicrobial resistance (AMR): identifying unmet clinical needs
Invited papers: 4 x 15 minutes focussed on vaccines

1330
LUNCH, NETWORKING & POSTER VIEWING

1430
Sponsored session

Parallel sessions
Session one: AMR rapid diagnostic tests: needs, target product profiles and technologies
1515
Clinical need
Professor Hermann Goossens, University of Antwerp
1535
Target Product
Dr Cassandra Kelly, Head of AMR & Outbreak, Foundation for Innovative New Diagnostics (FIND)
1555
Technologies: Overview of emerging technologies
1605
(A) ImmunoPoC and Minicare HCL: 15 minute fingerprick test for level and type of infection
Dr Liran Shani, ImmunoPOC
1615
(B) Pulmocheck: Test for bacterial infection
1625
Q&A
Session two: Reducing antibiotic usage through routine vaccination programmes
1515
The potential impact of a Group B streptococcus vaccine on the use of perinatal antibiotics
Professor Paul Heath, Professor of Paediatric Infectious Diseases, St George's Hospital, London
1535
Impact of the childhood influenza programme on disease burden in the elderly
Dr Richard Pebody, Head, Influenza and Other Respiratory Virus Surveillance Section, Public Health England, London
1535
Staph aureus vaccines
Dr David Wyllie, Senior Clinical Research Fellow, Group Head / PI, Consultant Physician, Member of congregation and Supervisor, University of Oxford, Oxford
Session three: Antimicrobial Susceptibility Testing Session
1515
Whats new in antifungal susceptibility testing
Professor Malcolm Richardson
1540
Development of disc diffusion test for anaerobes
Mr Trefor Morris
1605
Colistin resistance: our last hope
Dr Lim Jones
1630
Q&A

1645
REFRESHMENTS, NETWORKING & POSTER VIEWING

Parallel session
Session one: Routine and rapid surveillance systems
1715
What surveillance do we have for AMR?
Dr Berit Muller-Peabody, Public Health England, London
1735
Why is surveillance important after introducing vaccines?
Dr Michael Edelstein, Immunisation, Hepatitis and Blood Safety Department , National Infection Service, London
1755
Rapid surveillance in emergency situations: The Zika Experience
1815
Legacy planning - what did we learn from Ebola?
Dr Timothy Brookes, Public Health England, Porton Down, Salisbury
1835
Q&A
Session two: Next generation Antimicrobial Susceptibility Testing of Bacteria- the role of whole genome sequencing
1715
Rapid susceptibility testing: new phenotypic and non-WGS genotypic approaches
Dr Oskar Ekelund, Department of Clinical Microbiology and the EUCAST Development Laboratory, Kronoberg Region, Central Hospital, Växjö, Sweden
1745
WGS-based susceptibility testing for TB: from research to service delivery
Professor Grace Smith, Deputy Director, PHE London
1815
Should WGS be used for susceptibility testing of bacteria other than TB ?
Dr Matthew Ellington, Principal Clinical Scientist / Project Manager, PHE London

1830
WELCOME DRINKS AND NETWORKING
0730
BREAKFAST / COFFEE / TEA / BAGEL

0800
Clinical lessons: Invited papers: 4 x 15 minutes focussed on diagnostics

Plenary session: antimicrobial susceptibility testing
0900
Invited lecture: Antimicrobial susceptibility testing – then, now and the future
Dr Derek Brown, Scientific Secretary, EUCAST
0940
Q&A: What next for EUCAST
Professor Gunnar Kahlmeter, Past- Chair/Technical Data Co-ordinator and Dr Derek Brown, Scientific Secretary, European Committee on Antimicrobial Susceptibility Testing

Parallel sessions
Session one: AMR rapid diagnostic tests: development roadmaps, business models and behaviour change
0950
Development Roadmap
Dr Alex Van-Belkum, Corporate Vice President, bioMerieux
1010
Business Models
1030
Behaviour Change
Dr John Hays, Associate Professor, Erasmus University Medical Centre (Erasmus MC), Rotterdam, The Netherlands
Session two: vaccine access and uptake: the global challenge
0950
HPV vaccine and current controversies about vaccine uptake
Professor Margaret Stanley, Director of Research, Pathology, University of Cambridge
1020
Malaria Vaccine Initiative
Professor Didier Raoult, Aix-Marseille Université, Marseille, France
1050
Q&A

1100
REFRESHMENTS, NETWORKING & POSTER VIEWING

Concurrent sessions
Sponsored symposium one
Sponsored symposium two

1215
Plenary keynote lecture: Pneumococcal vaccine programme
Professor Keith Klugman, The Gates Foundation

1300
LUNCH, NETWORKING & POSTER VIEWING

Parallel sessions
Session one: The quiet revolution: the modernisation of laboratories - optimal use of existing diagnostics
1345
Point of care testing - lessons from procalcitonin
1405
MALDI-TOF and its impact on patient care
Dr Savita Gossain, Consultant Medical Microbiologist, Birmingham Heartlands Hospital
1425
Syndromic approaches to infection detection - tacman microarrays
Dr Martin Curran, Clinical Microbiology and Public Health Laboratory, Public Health England, Addenbrooke's Hospital, Cambridge
Session two: Vaccines against antibiotic resistant organisms
1345
Typhoid vaccine
Professor Andrew Pollard, Professor of Paediatric Infection and Immunity, University of Oxford, Oxford
1405
New TB vaccines
1425
HIV vaccine
Professor Sarah Rowland-Jones, Professor of Immunology, Nuffield Department of Medicine, University of Oxford

Plenary session: AMR game changers: next generation vaccines and diagnostics
1445
Emerging and experimental vaccines: Vaccinating against MRSA, e-Coli and C-Diff - where are we now?
1445
Diagnostics - the next best things and more

1545
CLOSING REMARKS
Top